Nurix Therapeutics holder reports 5.3% T. Rowe Price stake

T. Rowe Price Associates, Inc. reported beneficial ownership of common stock of Nurix Therapeutics, Inc. (NRIX).

Rhea-AI Filing Summary

T. Rowe Price Associates, Inc. reported beneficial ownership of common stock of Nurix Therapeutics, Inc. (NRIX). The firm reported holding 5,436,587 shares of common stock, representing 5.3% of the outstanding class. It reported sole voting power over 5,250,628 shares and sole dispositive power over 5,436,587 shares, with no shared voting or dispositive power. T. Rowe Price Associates stated that this filing should not be construed as an admission that it is the beneficial owner of these securities and expressly denied such beneficial ownership.

Key Figures

Shares beneficially owned: 5,436,587 shares Percent of class: 5.3% Sole voting power: 5,250,628 shares +1 more

4 metrics

Shares beneficially owned 5,436,587 shares Common stock of Nurix Therapeutics reported by T. Rowe Price Associates

Percent of class 5.3% Portion of Nurix Therapeutics common stock class reported as beneficially owned

Sole voting power 5,250,628 shares Shares of NRIX over which T. Rowe Price Associates has sole power to vote

Sole dispositive power 5,436,587 shares Shares of NRIX over which T. Rowe Price Associates has sole power to dispose

Key Terms

beneficial ownership, sole voting power, sole dispositive power, Schedule 13G, +1 more

5 terms

beneficial ownership financial

"declares and affirms that the filing of shall not be construed as an admission that Price Associates is the beneficial owner"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

sole voting power financial

"Sole Voting Power 5,250,628.00 6 | Shared Voting Power 0.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

sole dispositive power financial

"Sole Dispositive Power 5,436,587.00 8 | Shared Dispositive Power 0.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

Schedule 13G regulatory

"form_type": "SCHEDULE 13G""

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

CUSIP Number financial

"Title of class of securities: COMMON STOCK (e) | CUSIP Number(s): 67080M103"

A CUSIP number is a nine-character code that uniquely identifies a specific U.S. or Canadian stock, bond, or other security, similar to a barcode or a social-security number for a financial instrument. It matters to investors because it removes confusion between similar securities, ensures trades and settlements are applied to the correct issue, and helps locate official documents and transaction records quickly.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What ownership stake in NRIX does T. Rowe Price Associates report?

T. Rowe Price Associates reports beneficial ownership of 5,436,587 NRIX common shares, representing 5.3% of the class. This reflects a significant institutional position crossing the 5% reporting threshold for large shareholders.

How much voting power in NRIX stock does T. Rowe Price Associates have?

T. Rowe Price Associates reports sole voting power over 5,250,628 NRIX shares and no shared voting power. This means it can vote or direct the vote for those shares on its own authority.

What dispositive power over NRIX shares does T. Rowe Price Associates report?

The firm reports sole dispositive power over 5,436,587 NRIX shares and no shared dispositive power. Dispositive power refers to the ability to dispose of or direct the disposition of the shares.

Does T. Rowe Price Associates admit beneficial ownership of NRIX shares?

No. While reporting beneficial ownership information, T. Rowe Price Associates expressly denies being the beneficial owner of the NRIX securities referenced and states the filing should not be construed as such an admission.

When was the NRIX Schedule 13G for T. Rowe Price Associates signed?

The Schedule 13G related to NRIX was signed on 08/14/2026 by Ellen York, Vice President of T. Rowe Price Associates. This signature date confirms when the ownership information was formally certified.

What class of NRIX securities is covered in this Schedule 13G?

The filing covers common stock of Nurix Therapeutics, Inc., identified by CUSIP 67080M103. All share and percentage figures reported in the Schedule 13G relate specifically to this class of securities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/14/2026 - 10:40 AM Accepted by SEC EDGAR 08/14/2026 - 10:38 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

NURIX THERAPEUTICS INC

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

67080M103

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 67080M103

1

Names of Reporting Persons

T. Rowe Price Associates, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

MARYLAND

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 5,250,628.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 5,436,587.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,436,587.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.3 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: NURIX THERAPEUTICS INC
(b)	Address of issuer's principal executive offices: 1600 SIERRA POINT PKWY, BRISBANE, CA, 94005
Item 2.
(a)	Name of person filing: T. Rowe Price Associates, Inc.
(b)	Address or principal business office or, if none, residence: 1307 Point Street, Baltimore, MD 21231
(c)	Citizenship: Maryland
(d)	Title of class of securities: COMMON STOCK
(e)	CUSIP Number(s): 67080M103
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 5436587
(b)	Percent of class: 5.3 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 5250628
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 5436587
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. T. Rowe Price Associates, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

T. Rowe Price Associates, Inc.

Signature:	Ellen York
Name/Title:	Vice President
Date:	08/14/2026